Pharvaris (PHVS) investor relations material

Financial and operational updates

• Raised €132 million in an underwritten offering, extending cash runway into 2028 and fully funding both ODT and Prophy launches.

• Any perceived stock overhang has been addressed, with future data and approvals anticipated.

• Commercial organization plans to reach 70 staff by end of 2024 for on-demand launch, expanding to 90 by end of 2027 for Prophy.

• Senior hires are underway, with sales force hiring targeted for Q3/Q4.

• Launch readiness aims for near-instantaneous product availability post-approval.

Pipeline and clinical development

• NDA filing for ODT is on track for the first half of 2026; Prophy top-line readout expected by Q3 2026.

• Enrollment for AAE indication is progressing well, with a portfolio strategy targeting multiple indications.

• Phase III Prophy study is global, enrolling 81 participants, including adolescents and all HAE types.

• Targeting 80-85% efficacy in attack reduction to compete with injectables and lead the oral segment.

• XR formulation for Prophy aims to optimize once-daily dosing and minimize breakthrough attacks.

Clinical data and product differentiation

• RAPIDe-3 study met primary and all 11 secondary endpoints with statistical significance.

• Demonstrated rapid onset (17.5 min end of progression), symptom relief (1.28 hours), and complete resolution (<12 hours) with single-dose durability (83% efficacy at 20 mg).

• Differentiation from standard of care and competitors highlighted by superior efficacy and convenience.

• Deucrictibant offers flexibility for patients, including those needing to switch between on-demand and prophylactic therapy.

• Safety data supports use of both XR and IR formulations in combination for breakthrough attacks.